Metformax 850 (Metformin Hydrochloride)

Metformin works by suppressing the liver’s production of glucose and by increasing the sensitivity of muscle and fat cells to insulin, which promotes greater uptake of glucose from the bloodstream. It does not increase insulin secretion.

The dose of Metformax 850 is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

The safety of metformin during pregnancy or lactation has not been definitively established. Use should be considered only if the potential benefit justifies any potential risk to the fetus or infant, and it must be decided by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformax 850 belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, and SGLT2 inhibitors in its mechanism. It lowers glucose without stimulating insulin release, resulting in a lower intrinsic risk of hypoglycemia compared with insulin‑secretagogues.

Metformax 850 should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight and excessive heat to maintain product stability.

Metformax 850 is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with significant renal impairment, hepatic disease, or conditions causing tissue hypoxia. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain or unusual fatigue develop.

Metformax 850 is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or any component of the formulation.